SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gliatech (GLIA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jesse Schulman who wrote (930)9/7/1999 1:57:00 PM
From: scaram(o)uche  Read Replies (1) of 2001
 
H3 (GT 2331) has completed multi-dose phase I, and the company has budgeted a phase IIa for this quarter (don't know if they'll make it). You're correct, near-term additions to the product line would come from Adcon-P and/or Adcon-T/N.

The Adcon-P trials are pivotal, of course. For potential competition, you'll want to look at LCBM and determine if they would be expanding/creating a market that GLIA could then grab or establishing market share that would be forever *poof*.

The Janssen projects have become a perpetual sore point for me.... the molecules have been being optimized for preclinical testing for two years now.

The drive forward with the anti-properdin MAb is obviously sincere, and I've written to IR asking about the transporter publication and if that is indicative of more pipeline fill to come. No answer yet.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News